Vivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global Partners

Alliance Global Partners analyst Scott Henry lowered the firm’s price target on Vivos Therapeutics (VVOS) to $5.50 from $6 and keeps a Buy rating on the shares. Vivos’s Q4 results were within the firm’s expectations of slightly lower revenues with some “noise” in the quarter, the analyst tells investors in a research note. Results will take time to improve given the business model shift from dentists to sleep specialists, the firm says, adding that it expects “flattish” results in 1Q25 with sequential improvement thereafter.